Neurogenetic Pharmaceuticals, Inc. is a biotechnology and pharmaceutical company developing gamma-secretase modulators (GSMs)-- licensed from TPTX and with expended portfolio to include issued patents in the US, Europe, China, India, Japan, Australia, and other countries -- for the treatment of neurodegenerative disorders. GSMs technology is based on an innovative modulation of a key enzyme in the amyloid pathway, called ?-secretase. The company's approach alters the production of amyloid proteins from the toxic form found in AD brains (??42) to non-toxic forms (??37 and ??38), which do not contribute to plaque deposition. Neurogenetic's lead candidate, NGP 555, has been cleared by the FDA to begin clinical trials. This compound is expected to prevent the deposition of amyloid plaques in the brain, thereby precluding neuronal cell death and the dementia associated with AD. Future clinical trials will utilize specific ?? biomarkers and/or brain scanning as an early diagnostic and to monitor drug efficacy in clinical trials.
